Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314673 | 0.90 | TLR8 (0.34) | TLR8TLR7NAMPT | |
| SCHEMBL29314640 | 0.86 | SMN1; SMN2 (0.35) | ALDH1A1TLR8TLR7NAMPT | |
| SCHEMBL29314655 | 0.83 | TLR8 (0.33) | ALDH1A1TLR8TLR7NAMPT | |
| SCHEMBL29314685 | 0.83 | TLR8 (0.34) | TLR8TLR7GSK3BDYRK1ANAMPT | |
| SCHEMBL23037710 | 0.83 | TLR7 (0.40) | TLR8TLR7NAMPT | |
| SCHEMBL29314710 | 0.83 | NAMPT (0.33) | TLR8TLR7GSK3BDYRK1ANAMPT | |
| SCHEMBL29314631 | 0.83 | ABL1 (0.45) | ALDH1A1TLR8TLR7NAMPT | |
| SCHEMBL29320192 | 0.82 | TLR7 (0.39) | TLR8TLR7NAMPT | |
| SCHEMBL27194825 | 0.82 | NLRP3 (0.37) | TLR8TLR7 | |
| SCHEMBL29322691 | 0.82 | TLR8 (0.35) | TLR8TLR7NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | ALDH1A1 843/4885DDR1 3210/4885TLR8 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.